Iridex to Host Strategic Vision Call on April 16, 2025
Iridex (Nasdaq: IRIX), a leading provider of laser-based medical systems for glaucoma and retinal diseases, has announced a strategic vision call scheduled for April 16, 2025. The call will outline the company's strategic direction following Novel's recent strategic investment.
The conference call is set to begin at 2:00 p.m. PT / 5:00 p.m. ET. Investors can participate by dialing 888-596-4144 with conference ID: 9584140. Both a live and recorded webcast will be accessible through the 'Event Calendar' section on Iridex's investor relations website.
Iridex (Nasdaq: IRIX), un fornitore leader di sistemi medici basati su laser per il glaucoma e le malattie retiniche, ha annunciato una chiamata strategica programmata per il 16 aprile 2025. La chiamata delineerà la direzione strategica dell'azienda in seguito al recente investimento strategico di Novel.
La conferenza inizierà alle 14:00 PT / 17:00 ET. Gli investitori possono partecipare componendo il numero 888-596-4144 con l'ID conferenza: 9584140. Sarà disponibile sia una trasmissione in diretta che una registrazione attraverso la sezione 'Calendario Eventi' sul sito web delle relazioni con gli investitori di Iridex.
Iridex (Nasdaq: IRIX), un proveedor líder de sistemas médicos basados en láser para el glaucoma y enfermedades de la retina, ha anunciado una llamada de visión estratégica programada para el 16 de abril de 2025. La llamada describirá la dirección estratégica de la empresa tras la reciente inversión estratégica de Novel.
La conferencia comenzará a las 2:00 p.m. PT / 5:00 p.m. ET. Los inversores pueden participar marcando el 888-596-4144 con el ID de conferencia: 9584140. Habrá disponible tanto una transmisión en vivo como una grabación a través de la sección 'Calendario de Eventos' en el sitio web de relaciones con inversores de Iridex.
Iridex (Nasdaq: IRIX), 녹내장 및 망막 질환을 위한 레이저 기반 의료 시스템의 선도적인 공급업체가 2025년 4월 16일로 예정된 전략 비전 전화를 발표했습니다. 이 통화는 Novel의 최근 전략적 투자에 따른 회사의 전략적 방향을 설명할 것입니다.
컨퍼런스 콜은 오후 2시 PT / 오후 5시 ET에 시작됩니다. 투자자는 888-596-4144로 전화하여 회의 ID: 9584140으로 참여할 수 있습니다. Iridex의 투자자 관계 웹사이트의 '이벤트 캘린더' 섹션을 통해 생중계 및 녹화된 웹캐스트를 이용할 수 있습니다.
Iridex (Nasdaq: IRIX), un fournisseur de premier plan de systèmes médicaux basés sur des lasers pour le glaucome et les maladies rétiniennes, a annoncé un appel stratégique prévu pour le 16 avril 2025. L'appel décrira l'orientation stratégique de l'entreprise suite au récent investissement stratégique de Novel.
La conférence commencera à 14h00 PT / 17h00 ET. Les investisseurs peuvent participer en composant le 888-596-4144 avec l'ID de conférence : 9584140. Un webcast en direct et enregistré sera accessible via la section 'Calendrier des événements' sur le site web des relations avec les investisseurs d'Iridex.
Iridex (Nasdaq: IRIX), ein führender Anbieter von laserbasierten medizinischen Systemen für Glaukom und Netzhauterkrankungen, hat einen strategischen Vision-Call angekündigt, der für den 16. April 2025 geplant ist. Der Anruf wird die strategische Ausrichtung des Unternehmens nach der jüngsten strategischen Investition von Novel skizzieren.
Die Telefonkonferenz beginnt um 14:00 Uhr PT / 17:00 Uhr ET. Investoren können teilnehmen, indem sie 888-596-4144 mit der Konferenz-ID: 9584140 anrufen. Sowohl ein Live- als auch ein aufgezeichneter Webcast wird über den Abschnitt 'Veranstaltungskalender' auf der Investor-Relations-Website von Iridex zugänglich sein.
- None.
- None.
MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel’s strategic vision for the Company following Novel’s recent strategic investment in Iridex.
The Company’s management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When is Iridex (IRIX) hosting its strategic vision call in 2025?
How can investors join Iridex's (IRIX) April 2025 strategic vision call?
What will be discussed in Iridex's (IRIX) upcoming strategic vision call?
Where can investors find the recorded webcast of Iridex's (IRIX) strategic vision call?
